{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:14:14Z","timestamp":1791778454526,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T00:00:00Z","timestamp":1124928000000},"content-version":"vor","delay-in-days":5381,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Japanese Journal of Cancer Research"],"published-print":{"date-parts":[[1990,12]]},"abstract":"<jats:p>A cooperative randomized clinical trial to compare the effectiveness of multi\u2010drug combination chemotherapy (VMCP, vincristine\u2010melphalan\u2010cyclophosphamide\u2010prednisolone) with CP (cyclophosphamide\u2010prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was evaluated, the choice of chemotherapy (VMCP or CP) was not a significant prognostic factor associated with response or survival by uni\u2010 or multivariate analysis, and the difference between the survival curves of the treatment groups was only marginally significant. However, when the analysis was confined to stage III patients, the choice of chemotherapy became a significant prognostic factor associated with both response rate and survival, and the statistical difference between survival curves was significant. Taking the disease characteristics of multiple myeloma into consideration, the better result obtained with multi\u2010drug combination chemotherapy in the treatment of stage III patients is consistent with other studies supporting the superiority of multi\u2010drug combination chemotherapy for patients with overt systemic disease.<\/jats:p>","DOI":"10.1111\/j.1349-7006.1990.tb02697.x","type":"journal-article","created":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T09:21:23Z","timestamp":1124961683000},"page":"1320-1327","source":"Crossref","is-referenced-by-count":2,"title":["Multi\u2010drug Combination Therapy with Vincristine\u2010Melphalan\u2010Cyclophosphamide\u2010Prednisolone Was More Effective than Cyclophosphamide\u2010Prednisolone in Stage III Myeloma"],"prefix":"10.1111","volume":"81","author":[{"given":"Kazuyuki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hamajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumitsu","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Nagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8,25]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V54.1.13.13","article-title":"Improved survival of increased risk myeloma patients on combined triple alkylating agent therapy: a study of the CALGB","volume":"54","author":"Harley J. B.","year":"1979","journal-title":"Blood"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197910043011402"},{"key":"e_1_2_1_5_2","first-page":"73","article-title":"Comparison of two combination chemotherapy regimens for multiple myeloma: methyl\u2010CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone","volume":"64","author":"Cavagnaro F.","year":"1980","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_6_2","first-page":"1273","article-title":"Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma","volume":"66","author":"Abramson N.","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.8.453"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840201)53:3<583::AID-CNCR2820530336>3.0.CO;2-1"},{"key":"e_1_2_1_9_2","first-page":"270","article-title":"Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma","volume":"3","author":"Oken M. M.","year":"1984","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.7.836"},{"key":"e_1_2_1_11_2","first-page":"1061","article-title":"Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma","volume":"24","author":"Bergsagel D. E.","year":"1988","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5750.640"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1969.03150200094011","article-title":"Cyclophosphamide vs. melphalan in treatment of plasma cell myeloma","volume":"207","author":"Rivers S. L.","year":"1969","journal-title":"J. Am. Med. Assoc."},{"key":"e_1_2_1_14_2","first-page":"300","article-title":"Staging and kinetics of multiple myeloma","volume":"13","author":"Durie B. G. M.","year":"1986","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_15_2","first-page":"145","article-title":"Proposed guidelines for protocol studies. II. Plasma cell myeloma","volume":"4","author":"Chronic Leukemia\u2010Myeloma Task Force, National Cancer Institute","year":"1973","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_1_17_2","volume-title":"The Analysis of Binary Data","author":"Cox D. R.","year":"1970"},{"key":"e_1_2_1_18_2","first-page":"181","volume-title":"SUGI Supplemental Library User's Guide","author":"Harrell F. E.","year":"1983"},{"key":"e_1_2_1_19_2","volume-title":"SAS User's Guide. Statistics","year":"1982"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/52.1-2.203"},{"key":"e_1_2_1_22_2","first-page":"165","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N.","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_2_1_23_2","first-page":"87","article-title":"Regression models and life tables","volume":"34","author":"Cox D. R.","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"e_1_2_1_24_2","first-page":"267","volume-title":"SUGI Supplemental Library User's Guide","author":"Harrell F. E.","year":"1983"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1227"},{"key":"e_1_2_1_26_2","first-page":"2286","article-title":"Treatment of multiple myeloma (IV). Therapy with high\u2010dose intermittent administration of cyclophosphamide and prednisolone \u2014 follow\u2010up study of 10 years period","volume":"10","author":"Mizuno H.","year":"1983","journal-title":"Jpn. J. Cancer Chemother."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)31590-5"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006123022405"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","article-title":"Prognosis of asymptomatic multiple myeloma","volume":"148","author":"Alexanian R.","year":"1988","journal-title":"Arch. Intern. Med."},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.61.712.109"}],"container-title":["Japanese Journal of Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.1990.tb02697.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.1990.tb02697.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T20:11:20Z","timestamp":1698005480000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.1990.tb02697.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1990,12]]}},"alternative-id":["10.1111\/j.1349-7006.1990.tb02697.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.1990.tb02697.x","archive":["Portico"],"relation":{},"ISSN":["0910-5050"],"issn-type":[{"value":"0910-5050","type":"print"}],"subject":[],"published":{"date-parts":[[1990,12]]}}}